Today, we announced positive interim results from our ongoing 52-week open-label extension (OLE) of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies (DEEs). Additional detail can be found in our press release https://bit.ly/4efEgKU & OLE presentation https://bit.ly/3OEgIEd.
Fantastic update! Looking forward to the next steps
Awesome news!
congratulations!!!
Fantastic update!
Great news!
Board Chair, The FamilieSCN2A Foundation
1moExcited to hear this! Thank you for the innovative trial design that included multiple DEEs.